Toxicity of quinolones

Drugs

Volumn 58, Issue SUPPL. 2, 1999, Pages 37-42

  Stahlmann, Ralf ^a,b   Lode, Hartmut ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIARRHYTHMIC AGENT; CIPROFLOXACIN; CLINAFLOXACIN; FLEROXACIN; GREPAFLOXACIN; LOMEFLOXACIN; MAGNESIUM; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN;

ARTICULAR CARTILAGE; BACTERIAL INFECTION; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHELATION; CHONDROPATHY; CLINICAL TRIAL; CONFERENCE PAPER; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG TOLERABILITY; DRUG TOXICITY; EPIPHYSEAL CARTILAGE; GASTROINTESTINAL TOXICITY; HUMAN; INSOMNIA; INTRAVENOUS DRUG ADMINISTRATION; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PHOTOTOXICITY; QT INTERVAL; SKIN TOXICITY; TENDINITIS; TENDON DISEASE; TENDON RUPTURE; ULTRAVIOLET IRRADIATION; VERTIGO;

4-QUINOLONES; ANIMALS; ANTI-INFECTIVE AGENTS; FLUOROQUINOLONES; HUMANS;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 0032707693     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958991-00005     Document Type: Conference Paper

References (37)

1. Stahlmann R, Lode H. Safety overview. Toxicity, adverse effects, and drug interactions. In: Andriole VT, editor. The Quinolones, 2nd ed. San Diego, California: Academic Press, 1998: 369-415
2. Kawai Y, Matsubayashi K, Hakusui H. Interaction of quinolones with metal cations in aqueous solution. Chem Pharm Bull 1996; 44: 1425-30
3. Palù G, Valisena S, Ciarrocchi G, et al. Quinolone binding to DNA is mediated by magnesium ions. Proc Natl Acad Sci USA 1992; 89: 9671-5
4. Lode H. Drug interactions with quinolones. Rev Infect Dis 1988; 10 Suppl. 1: S132-6
5. Höffken G, Lode H, Wiley R, et al. Pharmacokinetics and bioavailability of ciprofloxacin and ofloxacin, effect of food and antacid intake. Rev Infect Dis 1988; 10 Suppl. 1: 138-9
6. Stahlmann R, Vormann J, Günther T, et al. Effects of quinolones, magnesium deficiency or zinc deficiency on joint cartilage in rats. Magn Bull 1997; 19:7-22
7. Stahlmann R. Safety profile of the quinolones. J Antimicrob Chemother 1990; 26 Suppl. D: 31-44
8. Norrby SR, Lietman PS. Safety and tolerability of fluoroquinolones. Drugs 1993; 45 Suppl. 3: 59-64
9. Christ W, Esch B. Adverse reactions to fluoroquinolones in adults and children. Infect Dis Clin Pract 1994; 3 Suppl. 3: S168-76
10. Stahlmann R, Schwabe R. Safety profile of grepafloxacin as compared with other fluoroquinolones. J Antimicrob Chemother 1997; 40 Suppl. A:83-92
11. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999; 28: 352-64
12. Langan CE, Cranfield R, Breisch S, et al. Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997; 40: 63-72
13. Chodosh S, Lakshminarayan S, Swarz H, et al. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily. Antimicrob Agents Chemother 1998; 42: 114-20
14. Springsklee M, Reiter C, Meyer JM. Safety and tolerability profile of moxifloxacin (MXF) [abstract P208]. 9th European Congress of Clinical Microbiology and Infectious Diseases; 1999 Mar 21-24: Berlin. Clin Microbiol Infect 1999: 140
15. Bowie WR, Willetts V, Jewesson PJ. Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin. Antimicrob Agents Chemother 1989; 33: 1778-82
16. Vincent J, Agin M, Laboy-Goral L, et al. Effect of dosing with food and bedtime dosing on the incidence of dizziness/lightheadedness with trovafloxacin in young, healthy, female subjects. Proceedings of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998; Sep 24-27; San Diego, California. Washington DC: American Society for Microbiology, 1998; A-086
17. Akahane K, Sekiguchi M, Une T, et al. Structure-epileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites. Antimicrob Agents Chemother 1989; 33: 1704-8
18. Takayama S, Hirohashi M, Kato M, et al. Toxicity of quinolone antimicrobial agents. J Toxicol Environ Health 1995; 45: 1-45
19. von Keutz E, Schlüter G. Preclinical safety evaluation of moxifloxacin, a novel fluoroquinolone. J Antimicrob Chemother 1999; 43 Suppl. B: 91-100
20. Schmuck G, Schürmann A, Schlüter G. Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model. Antimicrob Agents Chemother 1998; 42: 1831-6
21. de Sarro G, Nava F, Calapai G, et al. Effects of some excitatory amino acid antagonists and drugs enhancing y-aminobutyric acid neurotransmission on pefloxacin-induced seizures in DBA/2 mice. Antimicrob Agents Chemother 1997; 41: 427-34
22. Nakamura M, Abe S, Goto Y, et al. In vivo assessment of prevention of white-noise-induced seizure in magnesium-deficient rats by N-methyl-D-aspartate receptor blockers. Epilepsy Res 1994; 17: 249-56
23. Reinhart RA. Magnesium metabolism. A review with special reference to the relationship between intracellular content and serum levels. Arch Intern Med 1988; 148: 2415-20
24. Rhone Poulenc Rorer. Sparfloxacin monograph, Auckland: ADIS International, 1994
25. Domagala JM. Structure-activity and structure-side-effect relationship for the quinolone antibacterials. J Antimicrob Chemother 1994; 33: 685-706
26. Schwabe R, Lozo E, Baumann-Wilschke I, et al. Chondrotoxicity and target tissue kinetics of ofloxacin in immature rats after multiple doses. Drugs 1999; 58 Suppl. 2: 385-7
27. Förster C, Kociok K, Shakibaei M, et al. Quinolone-induced cartilage lesions are not reversible in rats. Arch Toxicol 1996; 70: 474-81
28. Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use - safety report. Pediatr Infect Dis J 1997; 16: 127-9
29. Pertuiset E, Lenoir G, Jehanne M, et al. Tolerance articulaire de la pefloxacine et de l'ofloxacine chez les enfants et adolescents atteints de mucoviscidose. Rev Rheumat 1989; 56: 735-40
30. Stahlmann R, Lode H. Safety of quinolones [letter]. Lancet 1998; 352 (9136): 1313
31. Syllm-Rapoport I, Strassburger I, Grüneberg D, et al. Über den experimentellen Magnesium-Mangel beim Hund. Acta Biol Med Germ 1958; 1: 141-63
32. Stahlmann R, Förster C, Shakibaei M, et al. Magnesium deficiency induces joint cartilage lesions in juvenile rats which are identical with quinolone-induced arthropathy. Antimicrob Agents Chemother 1995; 39:2013-8
33. Hayem G, Petit PX, Levacher M, et al. Cytofluorometric analysis of chondrotoxicity of fluoroquinolone antimicrobial agents. Antimicrob Agents Chemother 1994; 38: 243-7
34. Stahlmann R, Schwabe R, Pfister K, et al. Supplementation with magnesium and tocopherol diminishes quinolone-induced chondrotoxicity in immature rats. Drugs 1999; 58 Suppl. 2: 393-4
35. Kahn MF, Hayem G. Tendons and fluoro quinolones - unresolved issues. Rev Rhum Engl Ed 1997; 64: 437-9
36. Pierfitte C, Royer RJ. Tendon disorders with fluoro quinolones. Therapie 1996; 51:419-20
37. Shakibaei M, Pfister K, Schwabe R, et al. Effects of ofloxacin on the ultrastructure of Achilles tendon in rats. Drugs 1999; 58 Suppl. 2: 390-2